newsfilter
← Latest News
Business Wire·

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

U.S. Food and Drug Administration (FDA) provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) Company plans to advance cudetaxestat,